Changeflow GovPing Pharma & Drug Safety Modulators of Cystic Fibrosis Transmembrane Con...
Routine Notice Added Final

Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4225447A1 for Vertex Pharmaceuticals Incorporated, covering CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator compounds. The application was published April 1, 2026 with IPC classifications in pharmaceutical compositions (A61P 43/00, A61K 31/519) and specific chemical compounds (C07D 515/04). The patent lists 24 named inventors and designates all EPO contracting states.

What changed

The EPO published patent application EP4225447A1 for Vertex Pharmaceuticals covering CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator compounds and their use in treating cystic fibrosis. The application includes 24 named inventors and covers pharmaceutical compositions containing the disclosed compounds with IPC classifications indicating therapeutic applications.

For pharmaceutical companies and biotech firms developing cystic fibrosis treatments, this publication establishes a priority date and公开 visibility for Vertex's intellectual property around CFTR modulators. Generic manufacturers and competing developers should monitor examination proceedings to assess claim scope and potential invalidity grounds.

What to do next

  1. Monitor for patent grant and examination proceedings
  2. Review IP strategy for CFTR modulator compounds in Europe
  3. Track potential oppositions from generic manufacturers

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

Publication EP4225447A1 Kind: A1 Apr 01, 2026

Applicants

Vertex Pharmaceuticals Incorporated

Inventors

MCCARTNEY, Jason, ABELA, Alexander Russell, ABRAHAM, Sunny, ANDERSON, Corey Don, ARUMUGAM, Vijayalaksmi, CHAU, Jaclyn, CLEMENS, Jeremy, CLEVELAND, Thomas, COON, Timothy Richard, DINH, Andrew, DWIGHT, Timothy A., FANNING, Lev Tyler Dewey, FRIEMAN, Bryan A., GROOTENHUIS, Peter, HADIDA RUAH, Sara Sabina, ISHIHARA, Yoshihiro, KRENITSKY, Paul, MILLER, Mark Thomas, PIERRE, Fabrice, SILINA, Alina, TRAN, Joe A., VALDEZ, Lino, ZHOU, Jinglan

IPC Classifications

A61P 43/00 20060101AFI20220415BHEP C07D 515/04 20060101ALI20220415BHEP A61K 31/519 20060101ALI20220415BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4225447A1

Who this affects

Applies to
Pharmaceutical companies Investors Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination IP licensing Drug development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.